SUMMARY Nifedipine and captopril are potent vasodilators and may be expected to help left ventricular failure by reducing afterload. Nifedipine (20mg three times a day) and captopril (50 mg three times a day) were added to an optimal regimen of digitalis and diuretics in a double blind crossover trial in 18 cases of dilated cardiomyopathy. New York Heart Association functional class rating symptoms and exercise tolerance times improved on captopril but not on nifedipine. The reduction in pulmonary capillary wedge pressure and the increase of cardiac output on captopril indicated that the augmented functional capacity may have resulted in part from an improved performance of the left ventricle. Although there were comparable decreases in systemic vascular resistance and presumably in impedence to ejection by the left ventricle on both drugs, the dimensions of the ventricular cavity were found to be reduced by captopril and augmented by nifedipine, and only captopril reduced the afterload (wall stress). In addition, the force-length relation (between left ventricular end systolic stress and end systolic diameter) was shifted to the left of baseline by captopril and to the right by nifedipine, suggesting that muscle contractility was reduced by nifedipine and not by captopril.
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These results suggest that nifedipine and captopril have different effects on afterload and contractility and these may account for the different effects of these drugs on the performance of the heart and clinical responses.
Most vasodilators may be beneficial in both hypertension and cardiac decompensation. The angiotensin converting enzyme inhibitor, captopril, is such an example.'`3 The antihypertensive properties of the calcium channel blocking agents are well established,4 and nifedipine has been used to reduce ventricular afterload. [5] [6] [7] [8] Treatment of cardiac insufficiency in the advanced stage of dilated cardiomyopathy is still one of the most challenging tasks in clinical cardiology, and the poor prognosis justifies a search for more efficient methods of treatment. Although the combination of captopril with conventional treatment has been of benefit in many series of patients with refractory chronic congestive heart failure,9 -12 these series did
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For these reasons we have studied the effects of these two agents in dilated cardiomyopathy. We performed a detailed haemodynamic study of the different effects of captopril and nifedipine on blood vessels (in terms of arterial and venous muscle relaxation) and on the myocardium (in terms of changes in heart rate and contractility) in a crossover trial.
Patients and methods

PATIENTS
Twenty six patients with chronic congestive heart failure caused by dilated cardiomyopathy of unknown cause were considered to be eligible, but Patients continued to take the test drug three times a day as outpatients. Each day patients noted their symptoms in a diary and classified dyspnoea on a scale of 0 to 4 (0 when none occurred, 1 + with more than ordinary activity, 2 + with ordinary physical activity, 3 + dyspnoea at rest, and 4 + orthopnoea). We used the patient's dyspnoea grades to give a serial clinical function classification (from class I to IV).
For two months physical examination, exercise tests, and echocardiographic examination were performed each week. After this, patients were readmitted to hospital and non-invasive and invasive evaluations were repeated 90-120 min after the final dose of the agent. Then patients were switched to the other drug, and continued on it as outpatients. We Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy considered a washout period to be unnecessary in view of the long duration of treatment. The study continued as described earlier. No complications were noticed with repeated haemodynamic monitoring. The cardiothoracic ratio was measured on chest x rays obtained at the end of both treatment periods.
Both nifedipine (20mg) and captopril (50mg) were given in identical capsules in a double blind randomised fashion in both the short term and long term studies. Capsules containing an inactive preparation were given during the seven day run in period.
SAFETY
For the first three days of each drug treatment patients remained in hospital and blood pressure and symptoms related to hypotension were monitored. Hypotension with faintness on standing was experienced by three subjects while on nifedipine (one on nifedipine as second drug) and two while on captopril (one on captopril as second drug). In one of these, however, symptomatic hypotension was transient and he was able to continue on captopril; the other four patients could not and they were withdrawn from the trial. 
Results
Eighteen patients completed the study; all of them had had nifedipine and captopril for eight weeks each in a crossover study (Fig. 1) . Mean exercise tolerance times on captopril were significantly better than baseline values or values on nifedipine (Fig. 2) on nifedipine treatment ( Table 2 ). Changes in clinical class paralleled the changes in exercise tolerance in all but two patients. Baseline values for mean arterial pressure averaged 83 mm Hg, and the mean cardiac index for the group was reduced (2-5 I/min/m2). Pulmonary capillary wedge pressure was <20mmHg in all except one of the patients, and the mean value (12mm Hg) was lower than expected given the severity of con-700.
-'600--,"500- lar resistance and was associated with a 12", rise in cardiac index. Mean pulmonary arterial pressure, pulmonary arteriolar resistance, and the pulmonary capillary wedge pressure tended to decrease, although these changes were not statistically significant. After long term treatment the response was substantially different. In fact, changes from baseline in mean arterial pressure, and cardiac index were less pronounced and were no longer statistically signihcant; heart rate and pulmonary capillary wedge pressure showed a clear tendency to increase. The response to oral captopril was also greatest approximately 1 5 h after administration. In five patients the first dose induced considerable increases in cardiac index and stroke volume index and decreases in mean arterial pressure, heart rate, systemic vascular rcsistance, and pulmonary capillary wedge pressure, which were sustained after eight weeks of continuous treatment. Four patients had minimal haemodvnamic responses to the first 50 mg of the drug and also showed small changes when up to three times this dose was given. Despite the reduced initial response they continued on the standard protocol and were treated with the standard dosage. Repeat assessment after eight weeks of continuous treatment showed a spontaneous improvement of efficacy in three patients, in whom values became similar to those of the early responders in the same group. Because of this pattern, which has been reported by others, I 'I' overall haemodynamic changes from baseline that were present in the short term study were much more pronounced at long term re-evaluation (Fig. 3) . Figure 4 shows means for the circulatory variables that were recorded in the entire population at baseline and after long term treatment with both agents. The changes induced by captopril and nifedipine moved in the same direction, as shown in Fig. 3 . This indicates that the sequence of drug administration did not interfere with the quality of the response to the treatments. Cardiothoracic ratios measured by independent observers on standard chest x rays were significantly reduced after captopril. The mean control ratio was 0 575 compared with a mean ratio of 0 560 after two months of captopril treatment (p< 001).
Left ventricular end systolic circumferential wall stress (mean for the entire population with the exception of six patients) was significantly reduced by captopril and to a lesser extent and not significantly by nifedipine at the end of the treatment period; the force-length relation was shifted to the left after captopril but not after nifedipine (Fig. 5) .
No patients had to stop taking captopril or nifedipine during the study because of adverse reactions (Fig. 1) .
While on nifedipine five patients complained of headache and 11 reported palpitation that was described as disturbing by six. We do not know whether this symptom was associated with wors- ening arrhythmia because we did not evaluate this.
We also found an increase in body weight in 12 patients and enhancement of dependent oedema in 11 while they were on nifedipine. This latter effect, however, may not necessarily be due to cardiac causes. 17 Nifedipine also reduced mean serum potassium concentration and did not depress renal function (Table 2) . Captopril did not lead to the development of dependent oedema or increase body weight. Two patients on this treatment complained of a slight and transient taste alteration; in one patient serum creatinine concentration rose from 1-9 to 2-8 mg/dl; mean serum potassium rose from a baseline concentration of 4.Ommol/I to 4A4mmol/l (p<O001); this was also significantly higher than the concentration (3 7mmol/1) on nifedipine ( Table 2 ).
Discussion
In this study two potent vasodilators with different mechanisms of action were used to treat heart failure due to cardiomyopathy. Captopril or nifedipine were given with a fixed regimen of digitalis and diuretics in a double blind crossover trial. Captopril significantly improved the New York Heart Association functional class and exercise tolerance times. Agostoni, De Cesare, Doria, Polese, Tamborini, Guazzi heart failure treatment permitted patients who were incapacitated by symptoms to perform at least a moderate physical exertion. A training effect is unlikely to be responsible for this result because the physical tests were of short duration and infrequent. Nifedipine did not relieve symptoms, and made some patients worse. In the long term trial the significant reduction of the pulmonary capillary wedge pressure and the increase of cardiac output by captopril but not by nifedipine showed that at least part of the increased functional capacity might be the result of an improved performance of the left ventricle.
Did vasodilating potency or some other factor influence responses to the two drugs? In the short term study systemic vascular resistance was consistently reduced by nifedipine, cardiac output was raised, and the left ventricular filling pressure tended to fall. This pattern was similar to the response to nifedipine reported in patients with dilated cardiomyopathy and acute pulmonary oedema.5 7 During prolonged treatment, however, cardiac output did not improve and the pulmonary capillary wedge pressure rose substantially, indicating that the benefits of the reduced impedence to left ventricular ejection observed in the short term study were lost, even though the vasodilating action of nifedipine persisted. Changes in systemic vascular resistance after prolonged administration of captopril resembled those produced by nifedipine, but captopril improved the performance of the left ventricle, as indicated by the filling pressure-cardiac output relation.
Heart rate was increased (by an average of nine beats/min) on nifedipine and reduced (by an average of 11 beats/min) on captopril. This finding may be relevant to the different haemodynamic effects of the two agents since the greater the dysfunction of a ventricle the higher its sensitivity to changes in after- (Fig. 5) , even though the reduction of systemic vascular resistance and possibly of aortic impedence was similar with the two treatments.
The leftward shift of the force-length relation after captopril may indicate either a shift to a different point in the same basal stress-length line (which would indicate no change in contractility) or a displacement to the left of the force-length line itself (which would indicate improved contractility). 13 14 This relation tended to move rightward when patients were treated with nifedipine, indicating that some depression in contractility may have occurred.
The reduction in heart rate with captopril, which has been reported in several previous studies,9 16 20 may be due to the absence of a facilitating action of angiotensin II on the sympathetic neurotransmission,21 or to reduction of catecholamine release,17 or to venodilatation.-Captopril causes both venodilatation and arteriolar dilatation and hence heart rate may remain constant.17 If the adrenergic drive to the heart were really depressed by captopril when there was a concomitant improvement in cardiac function, the hypothesis advanced by some22 that catecholamines are deleterious in primary cardiomyopathies would be reinforced.
In conclusion, the therapeutic efficacy and low frequency of important adverse effects indicate that captopril is useful in patients with decompensated dilated cardiomyopathies that are refractory to conventional treatment. The poor or adverse responses to nifedipine that we have reported in this study discourage its use in such patients.
